Advancing Past Early Trials – Plus Shooting for Lifelong Immunity (Next Generation Covid Vax Update 12) - Absolutely Maybe
absolutelymaybe.plos.org
A massive funding boost from Project NextGen enables 3 phase 2b trials of next generation Covid vaccines to start in the US…

News from US Project NextGen:

The 3 vaccines from the USA chosen for Project NextGen are:

  • Gritstone Bio’s self-amplifying mRNA vaccine aiming to be “variant-proof”;
  • Covi-Vac/CoviLiv: A live virus intranasal vaccine from Codagenix; and
  • Castlevax viral vector intranasal vaccine, from a Mount Sinai Hospital spin-off.

Mucosal vaccines:

  • Mucosal vaccines are currently authorized for use in 6 countries: China, India, Indonesia, Iran, Morocco, and Russia. There are 5 of these vaccines: China has 2, and one of them is authorized in 3 countries:
    • Ad5-nCoV (Convidecia Air) Viral vector (adenovirus) vaccine by by CanSino (China)
    • BBV154 (iNCOVACC) Viral vector (adenovirus) intranasal vaccine by Bharat Biotech (India), using ChAd-SARS-CoV-2-S by Washington University in St Louis
    • DNS1-RBD (Pneucolin) viral vector intranasal vaccine, by Beijing Wantai BioPharm (China)
    • Razi Cov Pars Protein subunit by Razi Vaccine & Serum Research Institute (Iran)
  • 27 have reached clinical trial, with at least one of those has been discontinued.
  • 6 mucosal vaccines have reached phase 3 trials, including the 5 authorized vaccines.
  • TheModerateTankie [any]@hexbear.netEnglish
    6·
    10 months ago

    A new study just came out showing progress on a mucosal vaccine.

    An exciting development for a new Covid vaccine: inhaled single dose induces strong mucosal immunity and protection in multiple species, including non-human primates, and prevents transmission across all variants assessed It’s a dry powder for aerosol that does not have a cold chain requirement, big practical advantage

    https://nitter.net/EricTopol/status/1734971879512027542#m

    The vaccine encapsulates assembled nanoparticles comprising proteinaceous cholera toxin B subunits displaying the SARS-CoV-2 RBD antigen within microcapsules of optimal aerodynamic size, and this unique nano–micro coupled structure supports efficient alveoli delivery, sustained antigen release and antigen-presenting cell uptake, which are favourable features for the induction of immune responses.

    https://www.nature.com/articles/s41586-023-06809-8